Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding Aligos Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 39 | 46 | +7 |
| Shares | 26.5M | 27.3M | +787.4K (+3.0%) |
| Value | $25.3M | $23.9M | −$1.35M (−5.4%) |
New holders (10)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 1,000,000 | $874.0K | 0.13% |
| Silverarc Capital Management, LLC | 631,887 | $552.3K | 0.25% |
| Marshall Wace, LLP | 108,588 | $94.5K | 0.00% |
| Man Group plc | – | $49.5K | 0.00% |
| Susquehanna International Group, LLP | 24,594 | $21.5K | 0.00% |
| CWM, LLC | 16,891 | $15.0K | 0.00% |
| UBS Group AG | 2,329 | $2.04K | 0.00% |
| Simplex Trading, LLC | 1,579 | $1.00K | 0.00% |
| ZRC Wealth Management, LLC | 100 | $88 | 0.00% |
| Tower Research Capital LLC (TRC) | 92 | $0 | 0.00% |
Sold out (3)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| New York Life Investment Management LLC | 263,832 | $251.4K |
| Ergoteles LLC | 36,367 | $34.7K |
| Citigroup Inc | 85 | $81 |